National Jewish Medical And Research Center Shows Rush Immunotherapy Results In Allergen-Specific Changes In T Cells

April 21, 1997

DENVER-Rush immunotherapy targeting a single allergen makes distinct changes in T cells and stops allergic reactions, National Jewish Medical and Research Center physicians found, according to the April issue of the Journal of Allergy and Clinical Immunology.

"This study showed for the first time the T cell reaction to immunotherapy is specific," said Erwin Gelfand, M.D., head of the Department of Pediatrics at National Jewish and principal investigator of the study. "If you give too many antigens in desensitization, the immune system may not be able to distinguish between them. But attacking one trigger or a few triggers at a time can prevent the allergic reaction."

Rush immunotherapy consists of a number of injections given over a short time to desensitize a person to certain allergens, such as dust mites, cat dander or different types of plants.

Ten boys and girls, allergic to house dust mites and cat dander, were given rush immunotherapy for house dust mites only. When treatment ended, the children were desensitized to dust mites but not to cat dander, which showed that T cells can respond selectively to rush immunotherapy. In rush immunotherapy, T cells produce more interferon gamma, an element that lowers allergic responses, and shut off production of pro-allergic cytokines, which can cause wheezing, runny nose, sneezing and watery eyes.

"After rush immunotherapy you are more tolerant to an allergen you would have reacted to without desensitization," Dr. Gelfand said.

For more information on allergies, please call LUNG LINE, (800) 222-LUNG.

National Jewish Health

Related Immunotherapy Articles from Brightsurf:

MD Anderson researchers present immunotherapy advances at Society for Immunotherapy of Cancer Annual Meeting
Promising clinical results with combination treatments for patients with melanoma and lung cancer highlight immunotherapy advances being presented by researchers from The University of Texas MD Anderson Cancer Center at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting & Pre-Conference Programs (SITC 2020) .

Precision chemo-immunotherapy for pancreatic cancer?
Pancreatic cancer is highly lethal: according to the National Cancer Institute, only about 10 percent of patients remain alive five years after diagnosis.

Taking the itch out of cancer immunotherapy
Researchers from the University of Tsukuba have determined that PD-1 expression on CD8 T cells is the biological pathway that leads to psoriasis-like dermatitis, an unfavorable side effect of cancer immunotherapy with PD-1 inhibitors.

Prostate cancer: immunotherapy offers hope
An antibody for treating advanced prostate cancer improves progression-free survival in patients with metastasised, castration-resistant prostate cancer.

New immunotherapy to beat cancer
Sophie Lucas (University of Louvain de Duve Institute) and her team succeeded in neutralising a molecule that blocks the immune system against cancer.

New hydrogels for T-cell growth to be used in cancer immunotherapy
A team with the participation of researchers from the Spanish National Research Council (CSIC) has designed new hydrogels that allow the culture of T-cells or T-lymphocytes, cells of the immune system that are used in cancer immunotherapy since they have the capacity to destroy tumor cells.

The behavior of therapeutic antibodies in immunotherapy
Since the late 1990s, immunotherapy has been the frontline treatment against lymphomas where synthetic antibodies are used to stop the proliferation of cancerous white blood cells.

A blood test could predict who benefits from immunotherapy
A test which detects changing levels of tumour fragments in the blood may be an easy, non-invasive and quick way to predict who will benefit from immunotherapy, a treatment option for advanced cancers.

Immunotherapy safe for patients with COVID-19, cancer
Preliminary data from researchers at the University of Cincinnati Cancer Center show that immunotherapy doesn't necessarily worsen complications for patients with both COVID-19 and cancer.

A helping hand for cancer immunotherapy
Scientists at Sanford Burnham Prebys Medical Discovery Institute have demonstrated the therapeutic potential of PRMT5 inhibitors to sensitize unresponsive melanoma to immune checkpoint therapy.

Read More: Immunotherapy News and Immunotherapy Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to